Antibacterial agents: Patent highlights January to June 2004

Current Opinion in Investigational Drugs

Volumn 5, Issue 8, 2004, Pages 799-808

  Phillps, Oludotun A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

lactam antibiotics; Antibacterial agents; Macrolide; Oxazolidinone; Peptide; Peptide deformylase; Quinoline; Quinolone

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; MACROLIDE; OXAZOLE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL; DRUG ANTAGONISM; DRUG INDUSTRY; HUMAN; PATENT; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG INDUSTRY; HUMANS; MACROLIDES; OXAZOLES; PATENTS; QUINOLONES;

EID: 16644389678     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL: Trends in infectious diseases mortality in the United States. J Am Med Assoc (1996) 275(3):189-193.
2. World Health Organization (WHO): Deaths by cause, sex and mortality stratum in WHO regions for 2001. World Health Report Geneva, Switzerland (2002).
3. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr: Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis (2004) 38(9):1279-1286.
4. Guay DRP: Oriavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy (2004) 24(1):58-68.
5. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA: Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis (2003) 36(11):E146-E148.
6. Bozdogan B, Appelbaum PC: Oxazolidinone: Activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents (2004) 23(2):113-119.
7. Estrada B: The increase of macrolide resistance among streptococci. Infect Med (2002) 19(6):245.
8. Samaha-Kfoury JN, Araj GF: Recent developments in β-lactamases and extended spectrum β-lactamases. Br Med J (2003) 327(7425):1209-1213.
9. Lee N, Yuen K-Y, Kumana CR: Clinical role of β-lactam/β- lactamase inhibitor combinations. Drugs (2003) 63(14):1511- 1524.
10. Livermore DM: Determinants of the activity of β-lactamase inhibitor combinations. J Antimicrob Chemother (1993) 31(Suppl A):9-21.
11. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y: Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother (1993) 37(4):851-858.
12. Johnson AP: The future prospects of oxazolidinones. IDrugs (2003) 6(3):240-245.
13. Moellering RC: Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med (2003) 138(2):135-142.
14. Bobkova EV, Yan YP, Jordan DB, Kurilla MG, Pompliano DL: Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones. J Biol Chem (2003) 278(11):9802-9807.
15. Johnson AP, Tysall L, Stockdale MV, Woodford N, Kaufmann ME, Warner M, Livermore DM, Asboth F, Allerberger FJ: Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis (2002) 21(10):751-754.
16. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358(9277):207-208.
17. Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F, Press R: Linezolid-associated toxic optic neuropathy: A report of 2 cases. Clin Infect Dis (2003) 37(10):1389-1391.
18. Hutchinson DK: Oxazolidinone antibacterial agents: A critical review. Curr Top Med Chem (2003) 3(9):1021-1042.
19. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL: Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis (2004) 38(8):1058-1064.
20. Bronson JJ, Barrett JF: Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and cephem antibacterials in clinical development. Curr Med Chem (2001) 8(14):1775-1793.
21. Bryskier A: Novelties in the field of anti-infective compounds in 1999. Clin Infect Dis (2000) 31(6):1423-1466.
22. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF: Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis (2003) 36(8):963-970.
23. Henninger TC: Recent progress in the field of macrolide antibiotics. Expert Opin Ther Pat (2003) 13(6):787-805.
24. Agouridas C, Denis A, Augar J-M, Benedetti Y, Bonnefoy A, Bretin F, Chantot J-F, Dussarat A, Fromentin C, D'Ambrieres SG, Lachaud S et al: Synthesis and antibacterial activity of ketolides (6-O- methyl-3-oxoerythromycin derivatives): A new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J Med Chem (1998) 41(21):4080-4100.
25. Ma Z, Clark RF, Brazzale A, Wang S, Rupp MJ, Li L, Griesgraber G, Zhang S, Yong H, Phan LT, Nemoto PA et al: Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. J Med Chem (2001) 44(24):4137-4156.
26. Rotimi VO, Khoursheed M, Brazier JS, Jamal WY, Khodakhost FB: Bacteroides species highly resistant to metronidazole: An emerging clinical problem? Clin Microbiol Infect (1999) 5(3):166-169.
27. Rotimi VO, Mokaddas EM, Jamal WY, Khodakhast FB, Verghese TL, Sanyal SC: Susceptibility of 497 clinical isolates of Gram-negative anaerobes to trovafloxacin and eight other antibiotics. J Chemother (1999) 11(5):349-356.
28. Peláez T, Alcalá L, Martínez-Sanchez L, Muñoz P, García-Lechuz JM, Rodríguez-Créixems M, Bouza E: Metronidazole resistance in Clostridium difficile: A new emerging problem? ICAAC (1998) 38: Abs E-173.
29. Bartlett JG: Clostridium difficile: Clinical considerations. Rev Infect Dis (1990) 12(Suppl 2):S243-S251.
30. SANDOZ GMBH (Asher G, Heilmayer W, Schranz M, Wieser J): Cephalosporins. WO-2004007505 (2004).
31. FUJISAWA PHARMACEUTICAL CO LTD; WAKUNAGA PHARMACEUTICAL CO LTD (Ohki H, Okuda S, Yamanaka T, Ohgaki M, Toda A, Kawabata K, Inoue S, Misumi K, Itoh K, Satoh K): Cephem compounds. WO-2004039814 (2004).
32. BIOFERMA MURCIA (Geisecke UE): Enzymatic process for the preparation of β-lactams under kinetic control. WO-2004020652 (2004).
33. BIOFERMA MURCIA (Geisecke UE): Enzymatic process for the preparation of β-lactams under kinetic control. WO-2004020651 (2004).
34. RANBAXY LABORATORIES LTD (Kumar Y, Prasad M, Singh K, Misra S): Process for the preparation of cephem esters. WO-2004011471 (2004).
35. ORCHID HEALTH CARE (Kshirsagar RS, Boldhane SP, Jindal KC): Sustained release pharmaceutical composition of a cephalosporin antibiotic. WO-2004016250 (2004).
36. PFIZER PRODUCTS INC (Marfat A, Mcleod DG): β-Lactamase inhibitor prodrug. WO-2004018484 (2004).
37. NORTHWESTERN UNIVERSITY (Shoichet BK, Blaszczak LC): Sterically-awkward β-lactamase inhibitors. WO-2004037163 (2004).
38. PHARMACIA & UPJOHN CO (Gordeev MF, Singh U, Patel DV, May PD): Antimicrobial 1-aryl dihydropyridone compounds. WO-2004033449 (2004).
39. PHARMACIA & UPJOHN CO (Gordeev MF, Renslo A, Patel DV): Antimicrobial [3.1.0] bicyclic oxazolidinone derivatives. WO-2004033451 (2004).
40. PHARMACIA & UPJOHN CO (Hester JB Jr, Adams WJ, Stevens JC, Scott C, Gordeev MF, Singh U): Difluorothioacetamides of oxazolidinones as antibacterial agents. WO-2004002967 (2004).
41. PHARMACIA & UPJOHN CO (Hester JB Jr, Adams WJ, Stevens JC, Scott C, Gordeev MF, Singh U): Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents. WO-2004002479 (2004).
42. Chugh Y, Shetty N, Deshpande PK, Sindkhedkar MD, Jafri MA, Yeole RD, Shukla MC, Gupte SV, Patel MV, De Souza NJ: Antimicrobial oxazolidinones with improved pharmacokinetic profile and safety advantages. WO-2004007488 (2004).
43. Patel MV, Deshpande PK, Sindkhedkar MD, Gupte SV, Chugh Y, Shetty N, Shukla MC, Yeole RD, De Souza NJ: Antimicrobial cyano-(substituted)- methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites. WO-2004007489 (2004).
44. Lupin Ltd (Arora SK, Patil VJ, Nair PS, Dixit PP, Ajay S, Sinha RK): Oxazolidinone derivatives, process for their preparation and their use as antimycobacterial agents. WO-2004026848 (2004).
45. ORCHID CHEMICALS & PHARMACEUTICALS LTD (Agarwal SK, Guha MK, Pandey SS, Samuel MM): Novel antibacterial agents. WO-2004018439 (2004).
46. ORCHID CHEMICALS & PHARMACEUTICALS LTD (Agarwal SK, Akella SS, Visweswara S, Samuel MM): Oxazolidinone derivatives as antibacterial agents. WO-2004009587 (2004).
47. THE PROCTER & GAMBLE CO (Ledoussal B, Hu XE, Almstead J-IK, Gray JL): Antimicrobial quinolones, their compositions and uses. WO-2004014893 (2004).
48. AVENTIS PHARMA SA (Bacque E, Malleron J-L, Mignani S, Tabart M): Quinolyl propyl piperidine derivatives, preparation method and intermediates and compositions containing same. WO-2004011454 (2004).
49. MORPHOCHEM (Surivet J-P, Zumbrunn C, Hubschwerlen C): Novel compounds with antibacterial activity. WO-2004035569 (2004).
50. JANSSEN PHARMACEUTICA NV (Guillemont JEG, Van Gestel JFE, Venet MG, Poignet HJJ, Decrane LFB, Vernier DFJ): Quinoline derivatives and their use as mycobacterial inhibitors. WO-2004011436 (2004).
51. AVENTIS PHARMA SA (Becourt P, Boltri L, Cioloca N, De Luigi BS, Mapelli LG, Rabaglia L, Schwabe D): Taste masked oral composition of telithromycin. WO-2004009059 (2004).
52. BIOFRONTERA DISCOVERY GMBH (Prasad MR, Laatsch H, Helmke E, Hansske F, Simon W): Chalcomycin derivatives. WO-2004035598 (2004).
53. GLAXO WELLCOME (Berge JM, Frydrych CSV, Jarvest RL): Compounds. WO-2004039822 (2004).
54. BRISTOL-MYERS SQUIBB CO (Hudyma TW, Zheng X, Naidu BN, Sorenson ME, Regueiro-Ren A, Connolly TP, Matiskella JD, Kim OK, Zhang Y, Springer DM, Goodrich J et al): O-Derivatized nocathiacin derivatives. WO-2004004646 (2004).
55. BRITISH BIOTECH PHARMACEUTICALS LTD (Beckett RP, Wijkmans J, Krulle T): Antibacterial agents. WO-2004033441 (2004).
56. PHARMACIA & UPJOHN CO (Thorarensen A, Ruble CJ, Romero DL): Antibacterial agents. WO-2004018414 (2004).
57. PHARMACIA & UPJOHN CO (Thorarensen A, Ruble CJ, Romero DL): Antibacterial benzoic acid derivatives. WO-2004018461 (2004).
58. PHARMACIA & UPJOHN CO (Thorarensen A, Ruble CJ, Fisher JF, Romero DL, Beauchamp TJ, Northuis JM): Antibacterial benzoic acid derivatives. WO-2004018428 (2004).
59. GENESOFT PHARMACEUTICALS INC (Burli RW, Baird EE, Kaizerman JA, McMinn DL): Biaryl compounds having anti-infective activity. WO-2004012736 (2004).
60. DAINIPPON PHARMACEUTICAL CO LTD (Fujita M, Sakamoto M, Horiuchi N, Yamamoto T, Tomita K, Mizuno K, Niga T, Ito H, Kashimoto S): Proline derivatives. WO-2004018453 (2004).
61. ACTIVBIOTICS INC (Eisenstein B): Methods and reagents for treating infections of Clostridium difficile and diseases associated therewith. WO-2004019907 (2004)